GSK to rush out breast cancer treatment after trials success

GlaxoSmithKline's experimental breast cancer treatment, Tykerb, has proved so successful in drug trials it will be made available to patients in late stages of the disease, even before it gets the nod from regulators.

Europe's largest drug maker is set to dominate the world's biggest cancer conference in Atlanta today with data on Tykerb. Unlike Roche's $1.8bn-a-year drug, Herceptin, Tykerb can reduce the size of brain tumours caused by breast cancer, a problem for 30 to 40 per cent of women with the aggressive, recurring form of the cancer. The data also demonstrates that Tykerb works on patients where Herceptin has failed, and shows a significant increase in life expectancy. As a pill, Tykerb is also more convenient than Herceptin, which has to be injected.

US regulators have allowed GSK to offer Tykerb to doctors who wish to treat women suffering from advanced breast cancer, before regulatory approval for full-scale marketing of the pill, which is expected sometime next year. In the UK, patients could also be treated with Tykerb on "compassionate" grounds.

Final-stage clinical trials have shown that Tykerb, when given to women in combination with the chemotherapy drug Xeloda, slows the development of the cancer, nearly doubling the length of time patients live without the disease. The trials were stopped ahead of schedule last month because Tykerb worked so well.

But GSK still has a long way to go. Clinical trials to test Tykerb on early-stage breast cancer will take several years. Meanwhile, Herceptin was approved by the European Commission this week to fight early-stage breast cancer, and is likely to be cleared in the UK soon. That promises relief to many sufferers, some of whom have fought to get the drug on the NHS, at an estimated cost of £20,000 per patient a year.

Tykerb is believed to be far cheaper than Herceptin once it comes on to the market.

The Swiss pharmaceuticals giant Roche is developing combination treatments that could rival Tykerb. More than 1 million women are newly diagnosed with breast cancer every year worldwide - about 40,000 in the UK.

GSK's cancer business, until now relatively small, is likely to be transformed next year with the launch of Tykerb and other blockbuster drugs, such as the cervical cancer vaccine Cervarix and Eltrombopag, a blood-clotting agent in the treatment of breast cancer. The group is also developing a lung cancer vaccine that would stop the disease spreading.

The drug maker has emerged as one of the front-runners in the $15bn-plus bidding for the consumer healthcare arm of its US rival Pfizer, along with Johnson & Johnson, Reckitt Benckiser and Wyeth. The deal would transform GSK into the world's largest maker of non-prescription drugs. Second-round bids have to be in by Tuesday.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Operations Manager

£30000 - £38000 per annum: Recruitment Genius: They are a financial services c...

Guru Careers: Stockbroker

£Basic (OTE) + Uncapped Commission: Guru Careers: A Stockbroker (qualified / p...

Recruitment Genius: Financial Adviser

£20000 - £60000 per annum: Recruitment Genius: Are you recently QCA Level 4 qu...

SThree: Graduate Recruitment Resourcer

£20000 - £22500 per annum + OTE £30K: SThree: SThree Group have been well esta...

Day In a Page

Not even the 'putrid throat' could stop the Ross Poldark swoon-fest'

Not even the 'putrid throat' could stop the Ross Poldark swoon-fest'

How a costume drama became a Sunday night staple
Miliband promises no stamp duty for first-time buyers as he pushes Tories on housing

Miliband promises no stamp duty for first-time buyers

Labour leader pushes Tories on housing
Aviation history is littered with grand failures - from the the Bristol Brabazon to Concorde - but what went wrong with the SuperJumbo?

Aviation history is littered with grand failures

But what went wrong with the SuperJumbo?
Fear of Putin, Islamists and immigration is giving rise to a new generation of Soviet-style 'iron curtains' right across Europe

Fortress Europe?

Fear of Putin, Islamists and immigration is giving rise to a new generation of 'iron curtains'
Never mind what you're wearing, it's what you're reclining on

Never mind what you're wearing

It's what you're reclining on that matters
General Election 2015: Chuka Umunna on the benefits of immigration, humility – and his leader Ed Miliband

Chuka Umunna: A virus of racism runs through Ukip

The shadow business secretary on the benefits of immigration, humility – and his leader Ed Miliband
Yemen crisis: This exotic war will soon become Europe's problem

Yemen's exotic war will soon affect Europe

Terrorism and boatloads of desperate migrants will be the outcome of the Saudi air campaign, says Patrick Cockburn
Marginal Streets project aims to document voters in the run-up to the General Election

Marginal Streets project documents voters

Independent photographers Joseph Fox and Orlando Gili are uploading two portraits of constituents to their website for each day of the campaign
Game of Thrones: Visit the real-life kingdom of Westeros to see where violent history ends and telly tourism begins

The real-life kingdom of Westeros

Is there something a little uncomfortable about Game of Thrones shooting in Northern Ireland?
How to survive a social-media mauling, by the tough women of Twitter

How to survive a Twitter mauling

Mary Beard, Caroline Criado-Perez, Louise Mensch, Bunny La Roche and Courtney Barrasford reveal how to trounce the trolls
Gallipoli centenary: At dawn, the young remember the young who perished in one of the First World War's bloodiest battles

At dawn, the young remember the young

A century ago, soldiers of the Empire – many no more than boys – spilt on to Gallipoli’s beaches. On this 100th Anzac Day, there are personal, poetic tributes to their sacrifice
Dissent is slowly building against the billions spent on presidential campaigns – even among politicians themselves

Follow the money as never before

Dissent is slowly building against the billions spent on presidential campaigns – even among politicians themselves, reports Rupert Cornwell
Samuel West interview: The actor and director on austerity, unionisation, and not mentioning his famous parents

Samuel West interview

The actor and director on austerity, unionisation, and not mentioning his famous parents
General Election 2015: Imagine if the leading political parties were fashion labels

Imagine if the leading political parties were fashion labels

Fashion editor, Alexander Fury, on what the leaders' appearances tell us about them
Phumzile Mlambo-Ngcuka: Home can be the unsafest place for women

Phumzile Mlambo-Ngcuka: Home can be the unsafest place for women

The architect of the HeForShe movement and head of UN Women on the world's failure to combat domestic violence